Format

Send to

Choose Destination
See comment in PubMed Commons below
Dig Dis Sci. 2008 Jul;53(7):1988-93. doi: 10.1007/s10620-007-0003-2. Epub 2008 Apr 5.

Atorvastatin does not improve liver biochemistries or Mayo Risk Score in primary biliary cirrhosis.

Author information

1
Department of Medicine, The Mount Sinai School of Medicine, One Gustave L. Levy Place, Box 1633, New York, NY 10029, USA. cstanca@lmcmc.com

Abstract

Statin treatment reduces hypercholesterolemia and may be anti-inflammatory. Case reports noted decreased alkaline phosphatase and histological improvement following statin treatment in primary biliary cirrhosis. The objective of this study was to assess the long-term effects of statin treatment in primary biliary cirrhosis. A retrospective analysis compared clinical and biochemical data from 15 hypercholesterolemic individuals with primary biliary cirrhosis who were treated long-term with atorvastatin with an age and gender matched, primary biliary cirrhosis control group. A significant decrease in total cholesterol and low-density lipoprotein (LDL)-cholesterol (p < or = 0.002) was observed throughout atorvastatin treatment (median time 2.5 years). LDL-cholesterol levels in the control group were not significantly changed after 2 years (p > 0.050). No significant changes were noted in alanine aminotransferase (ALT), alkaline phosphatase, total bilirubin and Mayo Risk Score in either group (p > 0.05). Long-term atorvastatin treatment reduced LDL-cholesterol in primary biliary cirrhosis, but there was no evidence of any anti-inflammatory effect.

PMID:
18392679
DOI:
10.1007/s10620-007-0003-2
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Springer
    Loading ...
    Support Center